Samumed’s Moving Into Phase 3

It looks like we may have another approved treatment on the market within the next 2 years.

Today, Samumed released a newsletter addressing its program for androgenic alopecia, and stated that the company “has conducted an Investigator Meeting to initiate our upcoming 625-patient Phase 3 clinical trial.”



While the results from the phase 2 trial of SM04454 (Samumed’s drug for AGA) were not jaw-dropping, it can only be a positive occurrence for a hair growth drug to make it to phase 3 in 2018. If approved, SM04454 would provide a new treatment option for many people and also may “stack” well in current hair growth regimens. This means it may provide synergistic benefits when used in conjunction with other treatments such as minoxidil, finasteride, PRP, etc. SM04554’s safety is almost a sure thing at this point, it just needs to show enough efficacy in the phase 3 to move forward.

Like this: Like Loading...